Akari Therapeutics
AKTX
7 hedge funds and large institutions have $13.1M invested in Akari Therapeutics in 2014 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
13% less funds holding
Funds holding: 8 → 7 (-1)
19% less capital invested
Capital invested by funds: $16.2M → $13.1M (-$3.13M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$839K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$280K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$78K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$6K |
| 3 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$3K |
| 4 |
Citigroup
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Franklin Resources
San Mateo,
California
| $4.13M | – | – | – |
|
|
BBA
2
Baker Bros. Advisors
New York
| $4.11M | – | – | – |
|
|
BC
3
Broadfin Capital
New York
| $2.87M | – | – | – |
|
|
CAM
4
Cormorant Asset Management
Boston,
Massachusetts
| $1.49M | +$839K | +18 | +138% |
|
|
DCM
5
DAFNA Capital Management
Los Angeles,
California
| $268K | – | – | – |
|
6
HighTower Advisors
Chicago,
Illinois
| $179K | – | – | – |
|
|
PCM
7
Prelude Capital Management
New York
| $15K | – | – | – |
|
|
SM
8
Sabby Management
Miami Beach,
Florida
| $5.06K | +$280K | +6 | +6% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2K | – | – | – |
|
|
KCM
10
Knoll Capital Management
Miami,
Florida
| – | -$78K | -2 | Closed |
|
|
11
Citigroup
New York
| – | -$1K | – | – |
|
|
GSC
12
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$3K | – | – |
|
|
U
13
UBS
Zurich,
Switzerland
| – | -$6K | – | – |
|
AKTX Hedge Fund Activity: Q3 2014 in Review
7 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2014, worth a combined $13.1M — down 19% from $16.2M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of AKTX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Cormorant Asset Management, adding an estimated $839K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $78K sold.
- 7 institutional investors held Akari Therapeutics (AKTX) as of Q3 2014, down from 8 in Q2 2014.
- Funds reported $13.1M of Akari Therapeutics stock for Q3 2014, down 19% quarter-over-quarter.
- 0 funds opened new Akari Therapeutics positions in Q3 2014 and 1 closed out, a net change of -1 holder.
- The largest Akari Therapeutics buyer in Q3 2014 was Cormorant Asset Management, an estimated $839K added.
- The largest Akari Therapeutics seller in Q3 2014 was Knoll Capital Management, an estimated $78K sold.
Based on aggregated 13F filings for Q3 2014.